Epidemic Stevens-Johnson syndrome in HIV patients in Guinea-Bissau: A side effect of the drug-supply policy?

AIDS

Volumn 24, Issue 5, 2010, Pages 783-785

  Oliveira, Inés ^a,b   Jensen Fangel, Søren ^c   Da Silva, David ^d   Ndumba, Agostinho ^d   Medina, Candida ^d   Nanadje, Albino ^d   Rasmussen, Dlama N ^a   Rudolf, Frauke ^a   Wejse, Christian ^a,c   Da Silva, Zacarias J ^a,e   Sodemann, Morten ^a,c   Laursen, Alex L ^c  

^a Studies of the Epidemiology of Epilepsy in Demographic Surveillance Systems   (Guinea-Bissau)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d Ministry of Health   (Venezuela)

^e National Public Health Laboratory   (Guinea-Bissau)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; SULFONAMIDE; ZIDOVUDINE;

ANEMIA; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG UTILIZATION; EPIDEMIC; GUINEA-BISSAU; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LETTER; LIVER TOXICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEVERE CUTANEOUS ADVERSE REACTION; SKIN ALLERGY; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; VIRUS DETECTION; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; EPIDEMICS; FEMALE; GUINEA-BISSAU; HIV INFECTIONS; HUMANS; MALE; NEVIRAPINE; STEVENS-JOHNSON SYNDROME;

EID: 77949345505     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328335cead     Document Type: Letter

References (31)

1. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333:1600-1607.
2. de Maat MM, ter Heine R, Mulder JW, Meenhorst PL, Mairuhu AT, van Gorp EC, et al. Incidence and risk factors for nevirapine-associated rash. Eur J Clin Pharmacol 2003; 59 (5-6): 457-462.
3. Warren KJ, Boxwell DE, Kim NY, Drolet BA. Nevirapine-associated Stevens-Johnson syndrome. Lancet 1998; 351:567.
4. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008; 128:35-44.
5. Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, Naldi L, Viboud C, Roujeau JC. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 2001; 15:1843-1848.
6. WHO. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach [online] 2003 http://www.who.int/hiv/pub/prev-care/en/arvrevision 2003en.pdf. 17 May 2009.
7. Phanuphak N, Apornpong T, Teeratakulpisarn S, Chaithong-wongwatthana S, Taweepolcharoen C, Mangclaviraj S, et al. Nevirapine-associated toxicity in HIV-infected Thai men and women,including pregnant women. HIV Med 2007; 8:357-366.
8. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356:1423-1430.
9. Pujari SN, Patel AK, Naik E, Patel KK, Dravid A, Patel JK, et al. Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India. J Acquir Immune Defic Syndr 2004; 37:1566-1569.
10. Martin AM, Nolan D, James I, Cameron P, Keller J, Moore C, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1M0101 and abrogated by low CD4 T-cell counts. AIDS 2005; 19:97-99.
11. Pollard RB, Robinson P, Dransfield K. Safety profile of nevir-apine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther 1998; 20:1071-1092.
12. Bonnet F, Lawson-Ayayi S, Thiebaut R, Ramanampamonjy R, Lacoste D, Bernard N, et al. A cohort study of nevirapine tolerance in clinical practice: French Aquitaine Cohort, 1997-1999. Clin Infect Dis 2002; 35:1231-1237.
13. Ananworanich J, Moor Z, Siangphoe U, Chan J, Cardiello P, Duncombe C, et al. Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs. AIDS 2005; 19:185-192.
14. Montaner JS, Cahn P, Zala C, Casssetti LI, Losso M, Hall DB, et al. Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. J Acquir Immune Defic Syndr 2003; 33:41-46
15. MazhudeC,JonesS,MuradS,TaylorC,EasterbrookP.Femalesex but not ethnicity is a strong predictor of nonnucleoside reverse transcriptase inhibitor-induced rash.AIDS2002;16:1566-1568.
16. Bersoff-Matcha SJ, Miller WC, Aberg JA, van Der Horst C, Hamrick HJ Jr, Powderly WG, Mundy LM. Sex differences in nevirapine rash. Clin Infect Dis 2001; 32:124-129.
17. Antinori A, Baldini F, Girardi E, Cingolani A, Zaccarelli M, Di Giambenedetto S, et al. Female sex and the use of antiallergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy. AIDS 2001; 15:1579-1581.
18. Sabin CA, Fisher M, Churchill D, Pozniak A, Hay P, Easterbrook P, Williams I. Long-term follow-up of antiretroviral-naive HIV-positive patients treated with nevirapine. J Acquir Immune Defic Syndr 2001; 26:462-465.
19. Barner A, Myers M. Nevirapine and rashes. Lancet 1998; 351:1133.
20. Manosuthi W, Sungkanuparph S, Tansuphaswadikul S, Inthong Y, Prasithsirikul W, Chottanapund S, et al. Incidence and risk factors of nevirapine-associated skin rashes among HIV-in-fected patients with CD4 cell counts <250 cells/microL. Int J STD AIDS 2007; 18: 782-786.
21. Kiertiburanakul S, Sungkanuparph S, Charoenyingwattana A, Mahasirimongkol S, Sura T, Chantratita W. Risk factors for nevirapine-associated rash among HIV-infected patients with low CD4 cell counts in resource-limited settings. Curr HIV Res 2008; 6:65-69.
22. van Leth F, Andrews S, Grinsztejn B, Wilkins E, Lazanas MK, Lange JM, Montaner J. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS 2005; 19:463-471.
23. Gatanaga H, Yazaki H, Tanuma J, Honda M, Genka I, Teruya K, et al. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS 2007; 21:264-265.
24. Clark R. Sex differences in antiretroviral therapy-associated intolerance and adverse events. Drug Saf 2005; 28:1075-1083.
25. Littera R, Carcassi C, Masala A, Piano P, Serra P, Ortu F, et al. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS 2006; 20:1621-1626.
26. LiechtyCA, SolbergP,MwimaG,WereW,Weidle PJ, Mermin J. Nevirapine-induced Stevens-Johnson syndrome in a mother and son. AIDS 2005; 19:993-994.
27. Vitezica ZG, Milpied B, Lonjou C, Borot N, Ledger TN, Lefebvre A, Hovnanian A. HLA-DRB1M01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS 2008; 22:540-541.
28. Mansson F, Alves A, Silva ZJ, Dias F, Andersson S, Biberfeld G, et al. Trends of HIV-1 and HIV-2 prevalence among pregnant women in Guinea-Bissau, West Africa: possible effect of the civil war 1998-1999. Sex Transm Infect 2007; 83:463-467.
29. da Silva ZJ, Oliveira I, Andersen A, Dias F, Rodrigues A, Holmgren B, et al. Changes in prevalence and incidence of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau: is HIV-2 disappearing? AIDS 2008; 22:1195-1202.
30. Mehta U, Maartens G. Is it safe to switch between efavirenz and nevirapine in the event of toxicity? Lancet Infect Dis 2007; 7:733-738.
31. Manosuthi W, Thongyen S, Chumpathat N, Muangchana K, Sungkanuparph S. Incidence and risk factors of rash associated with efavirenz in HIV-infected patients with preceding nevir-apine-associated rash. HIV Med 2006; 7:378-382.